Benzinga | Mar 1, 2021 11:17AM EST

Jefferies Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $32

Jefferies analyst Chris Howerton initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $32.